130
Participants
Start Date
April 30, 2015
Primary Completion Date
October 31, 2016
Study Completion Date
October 31, 2017
Telbivudine
Telbivudine, 600mg, oral, daily
Adefovir dipivoxil
Adefovir dipivoxil 10mg, oral, daily
off-treatment follow-up
302 Military Hospital Of China, Beijing
Beijing Ditan Hospital, Beijing
BeiJing YouAn Hospital ,Capital Medical University, Beijing
Department of infectious disease, First Hospital of Peking University, Beijing
People's Hospital of Beijing University, Beijing
The Second Affiliated of ChongQing University of Medical Science, Chongqing
Department of Infectious Disease, Nanfang Hospital, Guangzhou
No. 8 People's Hospital In GuangZhou, Guangzhou
The Third Hospital of Sun Yat-Sen University, Guangzhou
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Xiangya Hospital Central-South Univrsity, Changsha
No.81 Hospital of PLA, Nanjing
First Hospital .Jilin Unniversity, Changchun
ShengJing Hospital of China Medical University, Shengyang
JiNan Infectious Diseases Hospital, Jinan
Changhai Hospital affiliated to Second Military Medical University, Shanghai
Huashan Hospital，Fudan University, Shanghai
Shanghai Ruijin Hospital, Shanghai
Tangdu Hospital, XiAn
The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou
Collaborators (1)
Major Science and Technology Special Project of China Twelfth-Five-Year Project
UNKNOWN
Novartis
INDUSTRY
Nanfang Hospital, Southern Medical University
OTHER